首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1663002

疫苗佐劑市場規模、佔有率和成長分析（按產品、佐劑類型、給藥途徑、疾病類型、應用、疫苗類型和地區）- 2025-2032 年產業預測

Vaccine Adjuvants Market Size, Share, and Growth Analysis, By Product, By Adjuvant Type, By Route Of Administration, By Disease Type, By Application, By Vaccine Type, By Region - Industry Forecast 2025-2032

出版日期: 2025年02月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球疫苗佐劑市場規模為 6.701 億美元，預計將從 2024 年的 7.1171 億美元成長到 2032 年的 11.5247 億美元，預測期內（2025-2032 年）的複合年成長率為 6.21%。

由於感染疾病的上升，包括新出現和重新出現的病原體，疫苗佐劑市場正在經歷顯著的成長。感染疾病的激增增加了對有效疫苗的需求，而佐劑是提高疫苗有效性的關鍵成分。隨著全球對預防性醫療保健的關注，尤其是自 COVID-19 以來，人們更加重視疫苗接種作為預防疾病的關鍵策略。佐劑透過延長抗原在注射部位存在的時間、活化免疫細胞和調節免疫反應發揮至關重要的作用，最終產生更強、更持久的免疫力。隨著研發帶來針對多種疾病的創新疫苗，疫苗佐劑市場將繼續擴大並提供豐富的成長機會。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司詳細資訊
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

GSK plc（UK）
SEPPIC（France）
Croda International Plc（UK）
SPI Pharma（USA）
Agenus Inc.（USA）
Phibro Animal Health Corporation（USA）
Aurorium（USA）
Dynavax Technologies Corporation（USA）
Novavax Inc.（USA）
Merck KGaA（Germany）
Vaxine Pty Ltd.（Australia）
Hawaii Biotech Inc.（USA）
CSL Limited（Australia）
OZ Biosciences（France）
InvivoGen（USA）
Allergy Therapeutics（UK）
EuBiologics Co., Ltd.（South Korea）
Pacific GeneTech Limited（USA）
Riboxx GmbH（Germany）
Oncovir, Inc.（USA）

結論和建議

簡介目錄

Product Code: SQMIG35I2155

Global Vaccine Adjuvants Market size was valued at USD 670.1 million in 2023 and is poised to grow from USD 711.71 million in 2024 to USD 1152.47 million by 2032, growing at a CAGR of 6.21% during the forecast period (2025-2032).

The vaccine adjuvants market is experiencing significant growth driven by the rising incidence of infectious diseases, including both newly emerging and reemerging pathogens. This surge in infectious diseases has heightened the demand for effective vaccinations, positioning adjuvants as critical components in enhancing immunization efficacy. With a global focus on preventive healthcare, particularly post-COVID-19, there is an increasing emphasis on immunization as a primary strategy for disease prevention. Adjuvants play a pivotal role by prolonging antigen presence at the injection site, activating immune cells, and modulating the immune response, which ultimately fosters a stronger and more sustained immunity. As research and development yield innovative vaccines targeting diverse diseases, the market for vaccine adjuvants is poised for continued expansion, presenting abundant opportunities for growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segments Analysis

Global Vaccine Adjuvants Market is segmented by Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type and region. Based on Product, the market is segmented into Emulsion Adjuvants, Pathogen Components, Saponin-Based Adjuvants, Particulate-Based Adjuvants and Other Adjuvants. Based on Adjuvant Type, the market is segmented into Organic Adjuvants and Inorganic Adjuvants. Based on Route Of Administration, the market is segmented into Intramuscular, Subcutaneous and Other Routes of Administration. Based on Disease Type, the market is segmented into Infectious Diseases, Cancer and Other Diseases. Based on Application, the market is segmented into Research Applications and Commercial Applications. Based on Vaccine Type, the market is segmented into Human Vaccines, Veterinary Vaccines and Other Animals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Adjuvants Market

The COVID-19 pandemic has heightened global health concerns, leading to a significant rise in the demand for vaccinations, particularly those incorporating adjuvants. This trend is driven by the necessity for more effective vaccination strategies to combat a variety of infectious diseases and new emerging pathogens, which are crucial for maintaining community immunity. Consequently, vaccine manufacturers are actively seeking innovative methods to boost the potency of their vaccinations, investing in cutting-edge adjuvant technologies to enhance their effectiveness. This ongoing pursuit for improved vaccination solutions is a key driver in the Global Vaccine Adjuvants market.

Restraints in the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market faces significant constraints due to stringent regulatory barriers that impact the licensing of these products. These strict regulations can lead to delays in the market entry of new adjuvants, ultimately increasing costs for manufacturers and creating additional challenges for business growth. Navigating the complex regulatory landscape often requires substantial resources, making it particularly difficult for smaller companies to comply with safety standards and establish a foothold in the market. This regulatory burden poses a notable hurdle, potentially stifling innovation and competition in the vaccine adjuvant sector.

Market Trends of the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market is witnessing a significant trend towards personalized immunization plans, marking a transformative shift in vaccination strategies. As researchers increasingly focus on tailoring vaccines to individual patient profiles-considering genetic variations and specific immune responses-this approach aims to enhance vaccine efficacy and patient outcomes. By employing targeted adjuvants designed for diverse patient populations, the market is expected to drive innovation and demand for customized solutions. This evolution reflects a broader trend of precision medicine in immunization, indicating a growing commitment to improving public health through more effective and personalized vaccination strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Patent Analysis

Global Vaccine Adjuvants Market Size by Product & CAGR (2025-2032)

Market Overview
Emulsion Adjuvants
Saponin-Based Adjuvants
Particulate-Based Adjuvants
Other Adjuvants

Global Vaccine Adjuvants Market Size by Adjuvant Type & CAGR (2025-2032)

Market Overview
Organic Adjuvants
Inorganic Adjuvants
Global Vaccine Adjuvants Market Size by Route Of Administration & CAGR (2025-2032)
Market Overview
Intramuscular
Subcutaneous
Other Routes of Administration

Global Vaccine Adjuvants Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Infectious Diseases
Cancer
Other Diseases

Global Vaccine Adjuvants Market Size by Application & CAGR (2025-2032)

Market Overview
Research Applications
Commercial Applications

Global Vaccine Adjuvants Market Size by Vaccine Type & CAGR (2025-2032)

Market Overview
Human Vaccines
- Infectious Diseases
- Therapeutic
Veterinary Vaccines
- Companion Animals
- Livestock Animals
Other Animals

Global Vaccine Adjuvants Market Size & CAGR (2025-2032)

North America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- US
- Canada
Europe (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

GSK plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEPPIC (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Croda International Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SPI Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Phibro Animal Health Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurorium (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxine Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hawaii Biotech Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OZ Biosciences (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InvivoGen (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergy Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EuBiologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific GeneTech Limited (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Riboxx GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncovir, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments